At a glance
ClinicalIndex Comparison RecordN/ACompleted· 505 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RIM - Rituximab in Maintenance
In Brief
An observational study evaluating Rituximab for Follicular Lymphoma. Completed, enrolled 505 participants across 1 site.
Detailed Summary
It is a non-interventional study with a duration of approximately 24 months per participant to investigate the therapeutic efficiency, safety and treatment regimens of Rituximab maintenance therapy in daily routine in participants with previously untreated, relapsed or refractory cluster of differentiation 20 (CD20)-positive follicular lymphoma (FL) in clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2009
Primary CompletionJun 2014
First PostedSep 2015
TodayJul 2026
First PostedSep 1, 2015
Enrollment StartSep 1, 2009
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 10.8 years ago
Interventions
Rituximabdrug